Published in Biotech Business Week, December 20th, 2004
The updated financial statements cover company business activities to the end of June 2004, during which Sinovac sales increased by 110% over the first 6 months of 2003.
Sales revenue is attributed to Healive, the only product of the company that is currently available in the market. The sales of this product increased from $1,090,856 for the first half of 2003 to $2,291,558 of the corresponding period of this year, equivalent to a 110% increase. The company...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.